If you’ve ever grabbed a tube of topical cream, eye ointment, or oral gel from a pharmacy shelf, you might not have given a second thought to the packaging holding that product. But as someone who’s spent the last 12 years building pharmaceutical tube packaging solutions, I can tell you: compatibility between a drug and its tube isn’t just a detail—it’s the difference between a product that works as intended and one that could harm patients, lose its efficacy, or even fail regulatory checks. Last year, we worked with a small biotech startup that almost pulled their first over-the-counter eczema cream because their initial tube supplier missed a critical compatibility red flag. The excipients in the cream’s formula were breaking down the tube’s inner liner, leaching tiny particles into the product, and altering the cream’s pH enough to make it irritate sensitive skin. That scare not only delayed their launch by three months but cost them thousands in wasted raw materials—and it’s the kind of story that drives everything we do at our packaging company. Today, I want to walk you through the concrete, science-backed steps we take to ensure pharmaceutical tube packaging compatibility, the common pitfalls I see brands and suppliers alike fall into, and how you can avoid that costly startup setback. Pharmaceutical Tube Packaging
First, let’s get one thing straight: pharmaceutical tube compatibility isn’t a one-size-fits-all check box. It’s a tailored, multi-stage process that starts before we ever touch a piece of plastic or aluminum, and it doesn’t end when the tubes roll off the production line. The core of compatibility boils down to two simple rules: the packaging must not contaminate the drug product, and the drug product must not degrade or damage the packaging’s structural integrity over its shelf life. Break either rule, and you’re looking at compliance failures, product recalls, or worse—patient harm.
Let’s start with the foundational step: pre-formulation compatibility testing, which we initiate as soon as a brand shares their drug formula, not when they’re finalizing packaging specs. Too often, brands pick a tube material first because it’s cheap or fits their brand aesthetic, then find out it clashes with their drug’s active pharmaceutical ingredient (API) or excipients. We skip that backwards approach entirely. First, we ask for three key pieces of data: the drug’s API and its concentration, all inactive ingredients (including pH, surfactants, preservatives, and any solvents like propylene glycol or ethanol), and the product’s intended shelf life—usually two to three years for most pharmaceuticals.
Once we have that, we narrow down the tube base materials, because not all plastics or metals are created equal for pharma use. For most topical products, we work with three primary materials: low-density polyethylene (LDPE), which is flexible, moisture-resistant, and the most common for over-the-counter creams; high-density polyethylene (HDPE), which is sturdier and often used for oral gels; and laminated aluminum-plastic tubing, which offers excellent light and barrier protection for photosensitive drugs like retinoids or certain antibiotics. But even the right base material isn’t enough—inner liners are non-negotiable for most prescription and sensitive products. Liners are thin, food- and pharma-grade polymer coatings that line the inside of the tube and act as a barrier between the drug and the base material, preventing leaching and chemical reaction.
Here’s where the first round of rigorous testing comes in. We don’t just test a sample of tube material against a blank solution; we test it against the actual, full drug formula. We call this “accelerated stability testing,” and it’s designed to mimic the conditions a product will face over its entire shelf life, compressed into a matter of weeks. The test follows guidelines from the International Council for Harmonisation (ICH), the global body that sets standards for pharma manufacturing, so it’s accepted by regulatory agencies like the FDA and EMA. For our testing, we fill three sets of identical tubes with the full drug formula, then age them at two extreme temperature and humidity conditions: 40°C (104°F) / 75% relative humidity (for short-term accelerated testing) and 25°C (77°F) / 60% relative humidity (for long-term, real-world simulation). We pull samples at set intervals: 1, 3, 6, 9, 12, 18, 24, and 36 months, depending on the product’s intended shelf life.
When we analyze those samples, we look for three critical signs of incompatibility. First, we test for leachables and extractables. Extractables are compounds that leach out of the tube material when exposed to harsh solvents during testing, while leachables are those that make their way into the actual drug product over time. We use high-performance liquid chromatography (HPLC) and gas chromatography-mass spectrometry (GC-MS) to detect even trace amounts of these compounds—levels as low as parts per billion. For reference, the FDA limits most leachables in pharma products to under 0.5 parts per million for most topical applications, so we’re working with a very small margin for error. In the 2022 case I mentioned earlier, the untested tube liner was leaching a silicone-based compound that showed up in the GC-MS results at 1.2 parts per million—just above the FDA threshold—so the startup had to reformulate both their cream and their tube.
Second, we test for pH and product integrity changes over time. A drug’s pH is critical, especially for topical products: a pH that shifts even 0.5 units can alter the product’s texture, reduce the efficacy of preservatives, and cause skin irritation. For the eczema cream, the original tube caused the cream’s pH to drop from 5.5 (ideal for sensitive skin) to 4.2 after three months, which is why it was stinging users. We also check for changes to the API: does the tube cause the active ingredient to break down? For example, retinoids, which are common in anti-aging and acne products, degrade rapidly when exposed to oxygen or light, so we test if the tube’s barrier layer is sufficient to keep light out and prevent oxidation. We also test for changes to the product’s physical properties: does the cream thicken, separate, or turn an off-color over time? Those are all red flags for incompatibility.
Third, we test the tube’s structural integrity. A tube that’s permeable to oxygen or moisture will allow air or water vapor to seep in, which can degrade the drug. For example, insulin pens sometimes come in tubes that aren’t properly sealed, so moisture can get in and break down the insulin. We perform water vapor transmission rate (WVTR) testing and oxygen transmission rate (OTR) testing, which measure how much of each gas passes through the tube material in a given period. For most topical drugs, we require WVTR of less than 0.5 g per square meter per day and OTR of less than 1 cm³ per square meter per day—numbers that are standardized by the ISO 11607, the global standard for packaging for medical devices and pharmaceuticals.
Once we pass that initial accelerated testing, we move to the next phase: real-world stability testing, which we conduct in parallel for at least the first 12 months. Even though accelerated testing is designed to mimic real conditions, there are variables—like temperature fluctuations during shipping, or exposure to sunlight in a retail display case—that can’t be fully replicated in a lab. We send small batches of test tubes filled with the drug to our client’s lab, where they store them in actual warehouse and display conditions, and do monthly quality checks. In one case, a client’s product passed our accelerated testing perfectly, but failed real-world testing because their product is shipped in the summer to markets in the American Southwest, where temperatures regularly hit 90°F. The tube’s liner, which performed fine at 40°C, softened at higher temperatures, allowing the drug to penetrate the material. That’s why we always collaborate closely with our clients on their distribution network and end-use conditions—one size doesn’t fit all.
Another key step in ensuring compatibility is adhering to regulatory standards, not just our own. For US-based brands, all pharmaceutical packaging must comply with FDA 21 CFR Part 210 and 211, which cover current good manufacturing practices (cGMPs) for drug products and packaging. For clients in the EU, that means compliance with the European Pharmacopoeia (Ph. Eur.) and ICH Q7 guidelines for active pharmaceutical ingredients. We keep our facilities ISO 9001 and ISO 15378 certified, which are the specific standards for primary packaging materials for pharmaceuticals, so every step of our process is documented and auditable. That’s non-negotiable for us—no cutting corners on documentation, because when the FDA shows up for an audit, you need to be able to prove exactly how you tested every tube, every batch, and what results you got.
I also want to talk about two common mistakes I see in the industry that lead to compatibility issues. First, assuming that all pharma-grade plastics are the same. A lot of suppliers offer “medical-grade” LDPE, but not all medical-grade is created equal. Some LDPE grades have additives like plasticizers or slip agents that are not approved for direct contact with pharma products, and can leach into the drug. We only work with raw materials that are certified by the USP Class VI standard, which is the US pharmacopeia’s highest standard for materials that come into direct contact with drugs, food, or other consumables. That certification means the material has been tested for toxicity, leachables, and purity to meet strict regulatory requirements.
Second, forgetting that the tube’s cap and seal are part of the compatibility equation. The cap and the crimped seal at the end of the tube create a closed environment for the product, so if they’re not compatible with either the drug or the tube material, you can get contamination. For example, a cap liner made from foam rubber might break down when exposed to a solvent in the drug, and tiny rubber particles can get into the product every time you squeeze the tube. We always test the cap and seal along with the tube, not as separate components. In the startup eczema cream case, the original supplier didn’t test the cap at all, and when we did, we found that the cap’s foam liner was releasing a preservative that altered the cream’s texture. It was a small detail, but it almost derailed the entire product.
At the end of the day, the goal of compatibility testing isn’t just to pass regulatory checks—it’s to ensure that patients get a safe, effective product every single time they use it. That’s why we don’t rush through testing for our clients, even if they’re under pressure to launch their product. In that 2021 eczema cream case, we worked with the startup to reformulate both their tube and their cream, found a liner that was compatible, and delivered the tubes on schedule, just three months after their original delay—no more, no less. The product launched in 2022, and we’ve continued to work with them as they expanded their line to other topical products.
If you’re a brand developing a new pharmaceutical product, or looking to switch your packaging supplier to avoid compatibility issues, the most important thing you can do is start the conversation about compatibility before you finalize your product formula. Don’t wait until you have a prototype tube to test—let your packaging supplier be a partner in your development process, not just a vendor. Ask for their full testing protocol, ask to see their regulatory certifications, and ask for case studies of products similar to yours that they’ve successfully packaged.
Laminated Aluminum Tube If you’re looking for a packaging partner that prioritizes compatibility, quality, and regulatory compliance above all else, we’re here to help. We work with small biotech startups and large multinational pharma companies alike, providing custom tube solutions, full compatibility testing, and end-to-end support throughout your product’s lifecycle. The details matter, and we don’t cut corners on the details that keep patients safe and products on the market.
References
- International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). ICH Q7: Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients; 2000.
- U.S. Food and Drug Administration (FDA). 21 CFR Parts 210 and 211: Current Good Manufacturing Practice for Finished Pharmaceuticals; 2023.
- International Organization for Standardization (ISO). ISO 11607: Packaging for Terminally Sterilized Medical Devices; 2019.
- European Directorate for the Quality of Medicines & HealthCare (EDQM). European Pharmacopoeia (Ph. Eur.) 5.1: Materials in Contact with Pharmaceutical Products; 2022.
- U.S. Pharmacopeial Convention (USP). USP Class VI Plastics for Food and Pharmaceutical Contact; 2023.
Shandong Bozhi Packaging Materials Co., Ltd.
As one of the leading pharmaceutical tube packaging manufacturers and suppliers in China, we also support customized service. Please feel free to wholesale high quality pharmaceutical tube packaging for sale here from our factory. For price consultation, contact us.
Address: Jinxinyuan, Heping Road, Zhangdian District, Zibo City, Shandong Province
E-mail: pharmapackaging@hotmail.com
WebSite: https://www.bozepackaging.com/
